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Abstract
Amino-N is preserved because of the scarcity and nutritional importance of protein. Excretion requires its conversion to ammonia, later
incorporated into urea. Under conditions of excess dietary energy, the body cannot easily dispose of the excess amino-N against the evo-
lutively adapted schemes that prevent its wastage; thus ammonia and glutamine formation (and urea excretion) are decreased. High lipid
(and energy) availability limits the utilisation of glucose, and high glucose spares the production of ammonium from amino acids, limiting
the synthesis of glutamine and its utilisation by the intestine and kidney. The amino acid composition of the diet affects the production
of ammonium depending on its composition and the individual amino acid catabolic pathways. Surplus amino acids enhance protein
synthesis and growth, and the synthesis of non-protein-N-containing compounds. But these outlets are not enough; consequently,
less-conventional mechanisms are activated, such as increased synthesis of NOz followed by higher nitrite (and nitrate) excretion
and changes in the microbiota. There is also a significant production of N2 gas, through unknown mechanisms. Health con-
sequences of amino-N surplus are difficult to fathom because of the sparse data available, but it can be speculated that the
effects may be negative, largely because the fundamental N homeostasis is stretched out of normalcy, forcing the N removal
through pathways unprepared for that task. The unreliable results of hyperproteic diets, and part of the dysregulation found
in the metabolic syndrome may be an unwanted consequence of this N disposal conflict.
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Introduction
When compared with the metabolism of carbohydrates
and lipids, amino acid metabolism in man has been only
sparsely studied in relation to overall energy metabolism.
The roles of protein in starvation(1,2) and malnutrition(3,4),
however, have received more attention; however, in any
case, our actual knowledge of N metabolism in man is
far more limited than the detailed information available
on energy partition between carbohydrate (glucose) and
lipids, including their regulation systems. Curiously, the
study of proteins has been neglected despite being a key
nutritional source of energy. Probably, the present situ-
ation of limited knowledge is a compounded consequence
of the relatively large number of different molecular
species, their easy interconversion, the multiple catabolic
paths followed by their hydrocarbon skeletons, the meth-
odological difficulties of tracing the fate of N, its close
relationship with protein turnover, a multiplicity of
functional amino acid pools coupled with an active inter-
organ metabolism, and last, but not least, an excessively
sketchy knowledge of their catabolic paths and regulation
in man (mammals).
Irrespective of the lack of information, the manipulation
of protein content of diets has been actively developed for
at least half a century, mainly by using hyperproteic very-
low-energy diets for the treatment of obesity(5,6), with
serious problems often arising from their application(7).
There has been a considerable utilisation of low-
carbohydrate diets, in which the protein component is con-
spicuous(8,9), but most of the discussion of their effects has
been centred on their ketogenic (i.e. lipid, absence of
carbohydrate) nature(10), the amino acids essentially being
considered potential gluconeogenic substrates(11), with
little impact on protein synthesis(12). More recently, the use
of hyperproteic diets(13) is again on the rise, but we still
lack the necessary basic knowledge to interpret the results
obtained, largely because of few systematic analyses and
the continued stress on their ketogenic nature(8,9).
However, under conditions of abundant food supply,
the main question is not how amino acids fare under con-
ditions of low energy availability, but the contrary: how the
metabolic machinery can override the strong protective
mechanisms preventing N wasting under conditions of
excess energy (i.e. lipid, carbohydrate and protein)
intake. There are few studies on how amino acids are
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used as substrates, especially on the fate of N under con-
ditions of excess energy intake or obesity. In the present
review, the main questions posed by the combination of
excess energy and amino-N availability are analysed
under the light of the scarce information available.
Amino acids as energy substrates: amino-nitrogen sparing
One of the most significant differences between what
our ancestors ate (i.e. the diet for which our digestive
system and metabolic energy partitioning are geared and
optimised) and the present-day diet is, in addition to
the overwhelming abundance of lipid, the constant presence
of protein, with a relatively high proportion of high-quality
protein. The tandem lipid–animal protein is substituting
progressively complex carbohydrate–low-quality plant pro-
tein as the main dietary staple. The proportion of protein
energy v. total energy intake is not too much different
today from the ancestral diet(14), but the total amount of
energy (after correcting for exercise) is higher, as is the
proportion of essential amino acids(15), whilst the relation-
ship between dietary amino acids v. glucose derived from
dietary sources tends to change as a direct consequence of
the substitution of starches by fats(16).
Our starvation resistance-prone mechanisms of adap-
tation preserve the use of amino acids as energy substrate
when there is sufficient energy in the gut(17). In addition,
both amino acids and glucose are spared when (if) the avail-
ability of lipid is high(18,19). In consequence, a diet rich in
energy and lipids, with a sizeable proportion of easily diges-
tible protein, rich in essential amino acids, will necessarily
result in difficulties to process and oxidise the amino acid
surplus, since we are metabolically conditioned to actively
preserve them. However, under excess-energy diets (includ-
ing protein), it is no longer necessary to retain so much
amino-N and essential amino acids. Amino acids are used
for energy when in relative excess(20,21), but the even
higher availability of energy from other sources strongly
limits our metabolic machinery to do so(22).
Amino acid catabolism tends to retain 2-amino-N, largely
because most amino acid hydrocarbon skeletons are oxi-
dised after transamination (typically to 2-oxoglutarate/
glutamate). However, a few amino acids yield directly
ammonia (Table 1). A quantitative analysis of several
common food proteins shows that, as expected, the theor-
etical direct yield of 2-amino-N is much higher than that of
direct ammonium production (Table 2). Thus, the parity
needed to synthesise our main N excretion product, urea,
requires (in a dietary equilibrium) the additional conver-
sion of a varying proportion of dietary 2-amino-N to
ammonium to reach the required (1:1) balance. The ratio
amino-N:ammonium-N in most dietary proteins is close
to 2 (Table 2), which leaves a wide margin for preservation
of N under conditions of starvation, but in the end requires
the mineralisation of about half of all amino-N to ammonia
under normal feeding conditions.
When active (exercise), muscle uses most of the body
energy available: its standard feed is glucose, but blood
lipids (fatty acids) limit glucose uptake and favour fatty
acid oxidation (insulin resistance)(23). Some amino acids
are oxidised in muscle (especially branched-chain(24)) in
the postprandial state to save glucose, but excess energy
hampers the process and its timing, since in fact there is
no real scarcity of glucose. Amino-N conversion into
ammonia is largely done in the liver and muscle through
the purine nucleotide cycle(25), and its operation is both
linked to active glycolysis(26) and increased AMP levels
(i.e. low ATP availability, partly compensated by the
action of adenylate kinase)(27); thus, under excess energy
availability, the cycle is largely idle. Glutamate dehydro-
genases play a key role in ammonium metabolism in
micro-organisms(28), and in the muscle of invertebrates(29).
However, Their role in ammoniagenesis in mammalian
muscle is limited, because of the predominance of the
purine nucleotide cycle(30) in this role, and the low
presence of the enzyme compared with the liver(31),
unaltered under starvation(32). In the liver (and kidney),
the activity of glutamate dehydrogenase is considerable(31),
but its function is clearly that of resynthesising glu-
tamate from 2-ketoglutaratre and excess ammonia, as
determined by direct studies and the analysis of its kinetic
constrictions(33–35).
Equilibrium between amino-nitrogen and ammonia for
urea synthesis
Thus, in muscle there is no other major way to produce
ammonia than the purine nucleotide cycle(30). In conse-
quence the muscle cannot use amino acids as an energy
source in significant amounts(36) and to use their N to pro-
duce and release glutamine. This is an important question,
since glutamine is themain formof blood transport of ammo-
nia, towards the splanchnic bed(37), i.e. intestine and kidney;
there, glutaminases free the ammonia again for its ultimate
disposal as urea(38), or as urinary ammonium ion(39). Lower
muscle synthesis of glutamine results, then, in lower splanch-
nic synthesis of carbamoyl-P, insufficient to maintain an
adequate flow of urea synthesis (Fig. 1). Alternative sources
of ammonium, such as the microbiota(40,41), which is in part
derived from glutamine(42,43), and the direct ammoniagenic
amino acids cited above (serine, threonine, glycine), help
maintain a steady albeit diminished rate of urea synthesis
in the intestine–liver system, a rate insufficient to cope
with the excess 2-amino-N pool generated by the diet and
limited amino acid disposal.
High amino acids in conjunction with high energy avail-
ability can generate a paradoxical scarcity of ammonia,
retaining a large and unshrinkable pool of amino-N
because the mechanisms that protect its conversion to
ammonia remain unaffected, and are both efficient and
effective (and potentially crippling). In the metabolic
syndrome (and in general, in energy-rich feeding), urea
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Table 1. Main amino acid (AA) catabolism pathways in man (adapted from Ferrer-Lorente et al.(130))*
AA Flow Pathway -NH2 Mean NH3 Mean
Gly 60 [Gly-cleavage system] ! methylene-THF ! methenyl-THF ! formate 0 0·35 1 0·60
35 [trans to] glyoxylate ! glycolate 1 0
10 [via UC conjugated with Arg] to creatine ! creatine-P ! creatinine 0 0
5 Other: excretion intact or as peptides, conjugation of xenobiotics and hormones 0 0
Ala 100 [trans to] pyr ! AcCoA ! [KC] 1 1·00 0 0·00
Ser 90 [Ser-dehydratase to] pyr ! AcCoA ! [KC] 0 0·05 1 0·95
5 [trans to] pyr-OH ! AcCoA ! [KC] 1 0
5 [cleavage to] Gly þ1-C 0 1
Cys 90 [trans þ desulfuration to] pyr ! AcCoA ! [KC] 0 0·00 1 0·90
10 Other: conversion to taurine 0 0
Met 100 [conjugated with ATP] ! S-adenosylMet ! [de-methylation (! 1-C) to] Hcys ! [conjugated with Ser] ! cystathionine
! (pyr ! AcCoA ! [KC]) þ oxobutyrate ! propionylCoA ! succ ! OAA ! pyr ! AcCoA ! [KC]
0 0·00 1 1·00
Thr 95 [Thr dehydratase to] oxobutyrate ! propionylCoA ! succ ! OAA ! pyr ! AcCoA ! [KC] 0 0·00 1 1·00
5 [Thr aldolase to] Gly þ acetaldehyde 0 1
Asp 50 [trans to] OAA ! pyr ! AcCoA ! [KC] 1 0·50 0 0·50
50 [via PNC or UC to] fumarate ! OAA ! pyr ! AcCoA ! [KC] 0 1
Asn 100 [asparaginase to] Asp 1 1·00 1 1·00
Glu 97 [trans to] oxoglutarate] ! OAA ! pyr ! AcCoA ! [KC] 1 1·00 0 0·00
3 [decarboxylation to] g-aminobutyrate ! succ ! OAA ! pyr ! AcCoA ! [KC] 1 0
Gln 100 [glutaminase to] Glu 1 1·00 1 1·00
Pro 50 [dehydrogen to] pyrroline-carboxylate ! Glu 1 0·95 0 0·00
45 [oxid to] pyrroline-carboxylate ! Glu 1 0
5 Excretion. Intact or as peptides 0 0
Hyp 45 [dehydrogen to] OH-pyrroline-carboxylate ! erythro OH-Glu ! OH-oxoglutarate ! (glyoxylate ! glycolate) þ (pyr !
AcCoA ! [KC])
1 0·90 0 0·00
45 [oxid to] pyrroline-carboxylate ! erythro OH-Glu ! OH-oxoglutarate ! (glyoxylate ! glycolate) þ (pyr ! AcCoA !
[KC])
1 0
10 Excretion. Intact or as peptides 0 0
Val 100 [trans to] oxoisovalerate ! isobutyrylCoA ! [BO] ! succCoA ! succ ! OAA ! pyr ! AcCoA ! [KC] 1 1·00 0 0·00
Leu 100 [trans to] oxoisocaproate ! [BO] ! (AcCoA ! [KC]) þ AcAc ! AcCoA ! [KC] 1 1·00 0 0·00
Ile 100 [trans to] oxomethylvalerate ! methylbutyrylCoA ! [BO] ! (AcCoA ! [KC]) þ propionylCoA ! succ ! OAA ! pyr
! AcCoA ! [KC]
1 1·00 0 0·00
Lys 90 [conjugated with oxoglutarate] ! saccharopine ! (Glu) þ oxoadipate ! AcAcCoA ! AcCoA ! [KC] 2 1·80 0 0·10
10 [deamination to] pipecolate ! oxoadipate ! AcAcCoA ! AcCoA ! [KC] 1 1
His 95 [deamination to] urocanate ! formiminoGlu ! [1-C] þ Glu 1 0·95 2 1·90
5 Other: excretion/conversion to histamine 0 0
Arg 100 [via UC to] Orn ! Glu-semi-aldehyde ! pyrroline-carboxylate ! Glu 1 1·00 0 0·00
Trp 70 [oxid to] kynurenine (þ formate) ! (Ala ! pyr ! AcCoA ! [KC]) þ oxoadipate ! crotonyl-CoA ! [BO] ! AcCoA
! [KC]
2 1·70 0 0·00
30 [trans to] indol-pyruvate ! indol-acetate (excreted) 1 0
Tyr 95 [trans to] OH-phenyl-pyruvate ! homogentisate ! (fumarate ! OAA ! pyr ! AcCoA ! [KC]) þ AcAc ! AcCoA
! [KC]
1 0·95 0 0·00
5 Other: [via dihydroxyphenylalanine. incorporation into] melanin, or catecholamines; excretion 0 0
Phe 95 [oxid to] Tyr 1 1·00 0 0·00
5 Other: largely [trans to] and excretion as phenylpyruvate) 1 0
THF, tetrahydrofolate; [trans to], transamination to; UC, urea cycle; AcCoA, acetyl-coenzyme A; [KC], Krebs or tricarboxylic acid cycle; pyr, pyruvate; [1-C], one-carbon pathways (essentially via THF); succ, succinate; OAA, oxaloacetate;
[dehydrogen to], dehydrogenation to; [oxid to], oxidation to; PNC, purine nucleotide cycle; [BO], b-oxidation pathway; AcAc, acetoacetate; AcAcCoA, acetoacetyl-coenzyme A.
* All values are estimations based on the scant data available from human subjects and other mammals; flow of amino acid catabolism via a given path depends largely on the size of amino-N pool, energy availability, metabolic
needs and the relative abundance of the amino acid (essential amino acids).
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synthesis is decreased(44), but there is not – either – a mas-
sive accumulation of body-N(45). Amino acids tend to be
preserved in spite of excess energy availability(46), but in
any case, the excess N is eventually lost, albeit not in the
canonical way of urea formation(47). A small but significant
proportion of N is excreted as N2 gas
(48,49) by means of, so
far, unknown pathways. In addition there is an increased
(but relatively small) loss of dietary amino-N in the form
of urinary nitrate and nitrite(50). Obligatory N losses also
include urinary losses of uric acid (from purine catabo-
lism(51)), creatinine and small proportions of peptides
and amino acids, as well as the ammonium ion, excreted
by the kidney (especially in acidosis)(52). Small amounts
of ammonium may be also excreted by the lungs(53).
Muscle also accumulates fat, near mitochondrial clusters
(C Cabot, K Pouillot, S Roy, MM Romero, R Vila`, MM Grasa,
M Esteve, JA Ferna´ndez-Lo´pez, M Alemany and X Remesar,
unpublished results) and adapts itself to the utilisation of
this main substrate (as well as to glucose, but to a lower
extent)(54,55). Exercise facilitates the massive utilisation of
energy and streamlines the oxidation of fats(56), but also
restores in part the production of ammonium via the purine
nucleotide cycle(57), thus increasing the flow of glutamine
to the splanchnic bed. However, a large proportion of
glucose, lipids and amino acids can not be taken up by any
of the above cited systems, leaving them unused and in
high serum concentrations, waiting for their storage as fat
in the last-recourse energy pool: white adipose tissue.
The nitric oxide pathway
NOz is synthesised from arginine by NOz synthases, yielding
citrulline(58). Excess N availability increases the synthesis of
ornithine(59), including the intermediate step of acetyl-
glutamate synthesis(60), which is also a key regulator of
carbamoyl-P synthase 2, and thus also participates in the
regulation of ammonium disposal(61). In consequence,
higher amino-N levels may increase those of arginine,
irrespective of low carbamoyl-P (i.e. low ammonium)
availability, shunting the NOz cycle from arginine to citrulline
and leaving out ornithine (and the synthesis of urea) (Fig. 2
(a) and (b)) (62). In cells that do not have a fully operative
urea cycle, the eventual regulation is even easier since it is
largely dependent on arginine availability(63).
It may be expected, then, that under high energy and
amino-N availability, the low ammonia concentrations(64)
Table 2. Amino acid (AA) content of a number of common food proteins, showing the -NH2:NH3 ratio that would be theoretically
generated from the complete oxidation in the body of its constituent amino acids*
AA content
(mmol/g protein)
-NH2 (mmol/g
protein)
NH3 (mmol/g
protein)
-NH2:NH3
ratio
‘Excess -NH2’
(% of -NH2)
Cheese 888 775 296 2·61 62
Potatoes 912 774 312 2·48 60
Maize 1 928 766 309 2·48 60
Maize 2 935 771 316 2·44 59
Cows’ milk 884 758 319 2·38 58
Pork 908 782 340 2·30 57
Spinach 923 748 337 2·22 55
Beef 933 770 349 2·21 55
Pilchard fish 919 770 348 2·21 55
Haddock fish 908 773 351 2·20 55
Lamb meat 928 764 351 2·18 54
Peas 896 750 344 2·18 54
Cassava 875 734 339 2·16 54
Lentils 900 745 347 2·14 53
Chickpeas 893 736 345 2·13 53
Soyabeans 899 744 352 2·11 53
Mollusks 920 743 356 2·09 52
Wheat 903 734 351 2·09 52
Chicken 909 748 360 2·08 52
Crustaceans 928 742 357 2·08 52
Tuna fish 903 774 375 2·06 52
Polished rice 915 723 357 2·03 51
Carrots 908 750 374 2·01 50
Beans 907 743 373 1·99 50
Hens’ eggs 914 713 359 1·98 50
Cabbage 944 724 375 1·93 48
Sesame 898 698 362 1·93 48
Hazelnuts 915 680 377 1·81 45
Apples 928 743 423 1·75 43
* The data have been calculated from standard protein amino acid composition tables(131) and the yield in free ammonium and transaminable 2-amino
groups resulting from the complete catabolism of these amino acids (Table 1). Since urea excretion requires equal proportions of amino and
ammonium, any -NH2:NH3 ratio above 1·00 represents a relative excess of amino groups, which may be further converted to ammonium via the pur-
ine nucleotide cycle or (in certain tissues and physiological conditions) by glutamate dehydrogenase. The ammonium yield of the proteins listed may
be underestimated, since most of the data gathered give a combined Glu þ Gln (Glx) value in the overall analyses. From the analysis of whole rat
protein(132) in which amide-N was analysed separately, we assumed, conservatively, and for the sake of these calculations only, that half the Glx
values corresponded to Gln and half to Glu; this correction has been included in the calculations and is reflected in the data shown in the Table.
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can not sustain an effective excretion of N through the urea
cycle(65), indirectly favouring an increased activity of the
NOz synthesis shunt. The excess NOz in blood vessels
(derived from the activity of erythrocyte and endothelial
NOz synthases)(66) may initially raise the blood flow, at
least locally, increasing the availability of oxygen and sub-
strates to the surrounding cells(67).
NOz is highly reactive and interacts with specific
proteins, such as guanylate cyclase(68), increasing the
production of cyclic GMP which activates protein kinase
G (PKG)(69) which, in turn, relaxes the smooth muscle of
small vessels and thus increases blood flow and lowers
arterial tension(70). This is the main recognised function
of NOz(71), but NOz is also able to bind cysteine residues
of other proteins, such as protein kinase A (PKA)(72),
which may induce a phantom adrenergic stimulation (i.e.
without the intervention of catecholamines or cAMP)(73).
Cytochrome c also efficiently oxidises NOz to nitrite(74).
Most of the NOz, however, rapidly reacts with oxyhaemo-
globin, eventually oxidising NOz to nitrate(75). Other highly
reactive NOx compounds, such as peroxynitrite
(76), are
formed by further oxidation with reactive oxygen species.
Part of these nitrogen oxides react with proteins, fatty acids
and other compounds yielding nitro-derivatives(77,78), often
short-lived, but which can cause permanent structural
changes(79).
Nitrite and other forms of nitrogen excretion
In the obese, the overall production and levels of NOz are
increased(80), as is its loss in the air breathed(81), but there
is a marked decrease in the excretion of urea(44).
A significant part of the difference in the N balance is
made up of N2 gas
(45,47,82). A possible source is the reaction
of nitrite and free amino acids, which in an acidic medium
yield N2 gas and 2-hydroxyacids
(83); this reaction has been
described to occur in the stomach lumen(84). However, this
reaction can hardly explain the large discrepancies found
in N balances. There must be another – larger – source
of N2 gas integrated in the amino acid metabolism, which
so far has not been discovered. We can hypothesise the
existence of an ‘emergence’ pathway, shunting the action
of NOz synthases towards the reaction of arginine with
nitrite, yielding citrulline and N2 gas under acidotic con-
ditions. This way, nitrite, the main active product of NOz
synthesis, would be rapidly removed and, at the same
time, the excess 2-amino-N would be decreased at the
expense of aspartate-derived arginine guanido-N; unfortu-
nately, no enzyme has been found (so far) able to carry out
this reaction, which nevertheless is known to proceed
spontaneously under low pH conditions(83).
Glucocorticoids may elicit counteractive actions(85) to
inhibit NOz synthesis, but catecholamines increase its pro-
duction(86). It is unclear whether NOz overproduction in
the obese can be a consequence of leptin-related catechol-
amine vasoconstriction(87), a consequence of enhanced
NOz synthesis through activation of endothelial or induci-
ble NOz synthases(88), or a lower bioavailability of NOz
favouring its increased synthesis(89,90).
Nitrite is considered a stabilised form of NOz(91), which can
yield NOz under hypoxic conditions by reacting with
Hb(92–94), thus helping increase blood flow to hypoxic
areas(95). Nitrite is also a source of NOz in the alimentary
canal(96,97); it is largely the product of reduction by the oral
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Fig. 1. Effect of excess dietary lipid on the main paths of N catabolism, driving to a decrease in the operation of the urea cycle because of lack of conversion of
2-amino-N to ammonium.
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biota of nitrate secreted by salivary glands(98). Nitrite-derived
NOz also kills bacteria in the stomach(99); in this acidic
medium, nitrite reacts with free amino acids yielding
N-nitroso-proline from arginine(100), as well as N2 as
indicated above(84).
The ‘obese’ microbiota(101,102) is probably a consequence
of this magnified effect of NOx
(103); changes in the gut
microbial ecosystem and composition also influence the
relationships with the host through modulation of the
immune response(104,105). The relative abundance of protein
debris in the intestine, a consequenceof diets rich in lipid and
protein, together with relatively scarce fibre and polysac-
charides, also affects the composition of the microbiota,
increasing the share of amino acid-related catabolism in the
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process of formation of stool(106,107). The resulting higher
pH, and the production of amines through amino acid decar-
boxylation(107), higher proportions of amines, ammonium,
as well as amine- and sulfide-related catabolites may also
help induce the development of intestinal cancer(108).
Health consequences of hampered nitrogen excretion
in the obese
The main problem posed by this question is the almost
absolute lack of information about the human patterns of
N excretion in overnutrition, obesity and the metabolic
syndrome. It has been found that a relative increase in diet-
ary protein at the expense of carbohydrates facilitates the
loss of weight(109,110), but we only know the short-term
macroscopic changes; the dynamics of 2-amino-N under
these conditions has not been studied.
We have mechanisms to adjust amino acid catabolism to
their relative abundance with respect to glucose(17), but the
large presence of lipids in the diet alters everything. Keto-
genic diets favour the excretion of ammonium in the urine
to counter the acidosis produced by ketone bodies(111,112),
and increase liver gluconeogenesis from amino acids(113),
but the problem of conversion of amino-N to ammonium
remains. The possible negative effects of a few truly hyper-
proteic (i.e. not ketogenic) diets(114), and their limited
effect on body fat point both to a generalised inefficiency
of the so-called ‘high-protein’ diets(115) and support the
relative danger of their uncontrolled application.
One of the most important aspects of amino acid metab-
olism is the synergistic complementarity of the roles of a
number of peripheral organs, the liver and the rest of
splanchnic bed organs(116,117). Hyperproteic diets may
induce changes in their roles in the absence of energy
overload, i.e. under conditions of active amino acid
catabolism(118). However, it is highly improbable that the
finely adjusted inter-organ relationships could be main-
tained under the pressure of high-energy diets, as the low
urea output seems to indicate; as a consequence the whole
body is affected by an excess of 2-amino-N.
There are few data on human subjects supporting an
increase in the synthesis of NOz in high-energy availability
conditions, except for an increased breath release of
NOz(81) and the consequent formation of nitrite and
nitrate(93,94). Perhaps the high levels of nitrite and the easy
interconversion of nitrite and NOz(99,119), a powerful vasodi-
lator(120), may be related to the ‘obesity paradox’, i.e. a
decreased severity of the consequences of heart failure in
the obese(121,122). The large presence of NOx in the alimen-
tary canal and its profound influence on the microbiota has
to produce, necessarily, changes in their properties and
functions: at least a different way to cope with unused sub-
strates and different relationships with the immune system-
controlled intestinal barrier. The latter may be related to the
higher levels of circulating lipopolysaccharide observed in
the metabolic syndrome(123), also linked to the maintenance
of low-key inflammation(124,125) caused by increased intesti-
nal bacteria activity(126). These findings hint to the postu-
lated excess 2-amino-N, in agreement with the higher
availability of amino acids and energy to increase protein
turnover(127,128) and to maintain a fully functional immune
system(129) observed in the metabolic syndrome.
Conclusions
Humans are fairly well prepared for amino-N scarcity: dietary
protein utilisation is maximised, and amino acid catabolism
is restricted in order to preserve body protein, and, with
that, to maintain the ability to function and survive. However,
the same mechanisms that make possible sparing amino acid
catabolism for energy seriously hamper the metabolism of
excess dietary amino-N under conditions of overfeeding
and excess available energy. Insulin resistance limits the
use of glucose when fats are readily available, and ample glu-
cose (energy) availability practically blocks the removal of
amino-N to form ammonia, the only, and narrow, canonical
way to dispose of excess N. The obese excrete less urea than
the lean, high-energy diets inhibit the urea cycle function,
but also alter the glucose–alanine cycle and the operation
of the purine nucleotide cycle; the path of conversion of
amino-N to ammonium is severely restricted. This creates a
surplus amino acid availability which enhances growth and
protein synthesis, but protein turnover simply stores, and
transamination changes, the hydrocarbon skeletons, preser-
ving the amino groups. Consequently, non-conventional
mechanisms are necessarily activated (there is no body sto-
rage of this surplus N). We do not know how this is accom-
plished, and only can suggest the possible implication of
NOz-increased synthesis, followed by higher nitrite (and
nitrate) secretion/excretion, and including the production
of N2 gas, through a mechanism so far unsolved.
The metabolic consequences of the imbalance between
amino- and ammonia-N are far-reaching and should be stu-
died in detail, since probably a number of unexplained
phenomena of the metabolic syndrome sink their roots in
the profound alteration of N homeostasis. The consequences
of excess dietary protein and our inability to dispose of it
have not been studied, but the indications obtained from
animal studies and the few data available suggest that
excess protein is harmful in the long term for humans.
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